Core Viewpoint - MaiPu Medical (301033.SZ) has announced that its R&D project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules" has officially entered the clinical trial phase [1] Group 1: Product Development - The product is intended for use in surgical procedures where traditional hemostatic methods, such as ligation, are ineffective or impractical [1] - It serves as an auxiliary hemostatic product to control bleeding from capillaries, veins, and small arteries [1]

Core Viewpoint - The company Maipu Medical has announced that its research project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules" has officially entered the clinical trial phase [1] Clinical Application - The product is intended for use in surgical procedures where traditional hemostatic methods, such as ligation, are not feasible or ineffective, serving as an auxiliary hemostatic product to control bleeding from capillaries, veins, and small arteries [1]

Core Viewpoint - The company, Maipu Medical (301033.SZ), has announced that its research project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules" has officially entered the clinical trial phase [1] Group 1 - The product is designed to be used as an auxiliary hemostatic agent in surgical procedures when traditional methods such as ligation are ineffective or cannot be performed [1] - It aims to control bleeding from capillaries, veins, and small arteries [1]

Core Viewpoint - The company Maipu Medical (301033.SZ) has announced that its research project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules" has officially entered the clinical trial phase [1] Group 1 - The product is designed to be used as an auxiliary hemostatic product in surgical procedures when traditional methods such as ligation are ineffective or cannot be performed [1] - It aims to control bleeding from capillaries, veins, and small arteries [1]

Core Viewpoint - The company has officially entered the clinical trial phase for its research project "Absorbable Regenerative Oxidized Cellulose Hemostatic Granules," which is classified as a Class III medical device [1] Group 1: Product Development - The product is intended for use as an auxiliary hemostatic agent in surgical procedures to control bleeding from capillaries, veins, and small arteries [1] - The completion of clinical trials will be followed by plans for registration application and commercialization [1] Group 2: Market Impact - The initiation of clinical trials will enhance the company's product line in the surgical field [1] - The specific impact on the company's future performance remains unpredictable at this stage [1]

关于医疗器械进入临床试验的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-071 广州迈普再生医学科技股份有限公司 关于医疗器械进入临床试验的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 申办者：广州迈普再生医学科技股份有限公司 试验用医疗器械名称：可吸收再生氧化纤维素止血颗粒 注册分类：第三类医疗器械 临床用途：在外科手术中，当结扎或其他传统的止血方法无法操 作或无效时，本产品可作为辅助止血产品用于控制毛细血管、静脉及 小动脉的渗血。 二、该项目后续审批流程 在该项目临床试验完成后，公司将开展相应的注册申报工作，以 及后续的产业化及上市销售工作。 三、对公司的影响及风险提示 公司"可吸收再生氧化纤维素止血颗粒"临床试验的开展，对丰 广州迈普再生医学科技股份有限公司（以下简称"公司"）的研 发项目"可吸收再生氧化纤维素止血颗粒"于近期正式进入临床试验 阶段，现将具体情况公告如下： 一、该项目临床试验的基本情况 关于医疗器械进入临床试验的公告 富公司其他外科领域产品线具有积极意义，公司将按照国家器械注册 的相关规定和要求开展临床试验 ...

关于参加网上集体接待日活动的公告 证券代码：301033 证券简称：迈普医学 公告编号：2025-070 广州迈普再生医学科技股份有限公司 关于参加 2025 广东辖区上市公司投资者 网上集体接待日活动的公告 关于参加网上集体接待日活动的公告 广州迈普再生医学科技股份有限公司 董事会 2025 年 9 月 16 日 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，广州迈普再生医学科技股份 有限公司（以下简称"公司"）将参加由中国证券监督管理委员会广 东监管局、广东上市公司协会联合举办的"向新提质 价值领航—— 2025 年广东上市公司投资者关系管理月活动投资者集体接待日"活 动。现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演" 网站（https://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（周五）15:30-17:00。 届时公司董事、总经理王建华先生，董事、副总经理、财务总监 骆雅红女士以及董事、副总经理、董事会秘书龙小燕女士将出席本次 交流活动，欢迎 ...

Core Insights - The company reported strong revenue growth in the first half of 2025, with revenue reaching 158 million yuan (+29.28%) and net profit attributable to shareholders at 47 million yuan (+46.03%) [1] - New products have become a key driver of growth, particularly in the international market, where overseas revenue increased by 50.96% [2][4] Financial Performance - In Q2 2025, revenue was 84 million yuan (+29.66%), with net profit attributable to shareholders at 23 million yuan (+32.62%) [1] - The overall gross margin for the first half of 2025 was 80.59%, an increase of 1.74 percentage points year-on-year [3] - The net profit margin improved to 29.98%, up by 3.44 percentage points, driven by cost optimization [4] Product Performance - Revenue from absorbable regenerated oxidized cellulose and medical glue reached 38.32 million yuan (+169.66%), becoming a core driver of performance [2] - The company’s core product, absorbable regenerated oxidized cellulose, expanded its application range, which is expected to support domestic market penetration [2] Market Expansion - Domestic revenue was 120 million yuan (+23.84%), while overseas revenue was 38 million yuan (+50.96%), indicating strong international market performance [2] - The company has expanded its reach to over 100 countries and regions globally [2] Cost Management - Sales expense ratio decreased to 17.68% (-0.98 percentage points), management expense ratio decreased to 19.23% (-5.11 percentage points), and financial expense ratio reduced to -0.93% (-0.81 percentage points) [3]

Group 1 - The core viewpoint emphasizes the need to redefine talent criteria beyond traditional academic qualifications, highlighting that even individuals with lower degrees can solve critical technical issues for companies, thus being considered scarce talent [1] - The chairman of MaiPu Regenerative Medicine Technology Co., Ltd., Yuan Yuyu, suggests that Guangdong should allow innovative leading enterprises to conduct provincial talent plans with self-assessment and self-recognition, granting companies greater autonomy in talent evaluation [1] - Yuan proposes a talent evaluation mechanism where selected technology-driven "chain leader" enterprises can determine talent standards, as market competition can validate suitable high-end talent for the industry [1] Group 2 - Guangdong is intensifying its talent acquisition efforts, launching the "Million Talents Gather in South Guangdong" initiative, which includes autumn recruitment activities across multiple cities to attract young talent nationwide [2] - Yuan emphasizes that talent must be integrated with innovation platforms, stating that without such platforms, talent cannot realize its value, thus urging enterprises to play a significant role in attracting talent [2] - The province aims to enhance support for existing technology talent teams, assist small and medium-sized enterprises in attracting talent, and promote the retention of high-level and young core talents within these companies [2]

北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2025 年第二次临时股东会的 法律意见书 二〇二五年九月 北京市中伦（广州）律师事务所 关于广州迈普再生医学科技股份有限公司 2025 年第二次临时股东会的 法律意见书 致：广州迈普再生医学科技股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州迈普再生医 学科技股份有限公司（以下简称"公司"）委托，指派章小炎律师和孙巧芬律师 （以下简称"本所律师"）对公司 2025 年第二次临时股东会（以下简称"本次 股东会"）的合法性进行见证并出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法 ...